Available Until 10/24/2023

Pharmacotherapy Review Course, Pract Exam, and Core Therapeutic Modules Package (No Recert Credit) (Cert # L229272)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 10/26/2022
Content Release Date: 11/23/2022
Expiration Date: 10/24/2023
Activity Type: Application-based
CE Credits: 33 contact hours (ACPE only)
Activity Fee: $425 (ASHP member); $625 (non-member)

Activity Overview

These activities will be recorded during a live educational event on December 3-4, 2022 at the Midyear Clinical Meeting in Las Vegas. Learners who claim the credit for the live activities should not claim credit for these home study activities. Those recordings will be added on 2/1/2022.

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Pharmacotherapy Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for in‐depth review of pharmacotherapy issues by:

  • Reviewing pertinent clinical topics and practice skills
  • Providing exam practice questions
  • Listing valuable references for further study

This course is NOT intended for those obtaining recertification credit. To earn recertification credit, please see courses here: http://elearning.ashp.org/catalog/ptherapy-recert 

These activities are part of the ASHP professional development program.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below. 

Review Course

These activities will be recorded during a live educational event on December 3-4, 2022 at the Midyear Clinical Meeting in Las Vegas. Those recordings will be added on 2/1/2022.

This course consists of 11 activities (see table below) and provides up to 16 contact hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements. To help you further prepare, this package includes a compilation of practice questions in the same format and rigor to help you prepare for the BPS Specialty Examination.

Learning Activity

ACPE Number

Contact Hours (ACPE)

ACPE Expiration Date

Cardiovascular Disease: Primary Prevention Case

0204-0000-22-605-H01-P

1.5

12/03/2025

Cardiovascular Disease: Secondary Prevention Case

0204-0000-22-606-H01-P

1.5

Complex Heart Failure Case

0204-0000-22-607-H01-P

1.5

Providing Safe and Effective Pharmacotherapy: Key Regulatory and Quality Approaches

0204-0000-22-608-H05-P

1.5

Research Methods and Data Analysis 

0204-0000-22-609-H04-P

1.5

Oncology and Supportive Care Case

0204-0000-22-610-H01-P

1.5

Complex Nursing Home Patient Case

0204-0000-22-611-H01-P

1.5

Complex HIV/AIDS Case

0204-0000-22-612-H02-P

1.5

Complex Pediatric Asthma Case

0204-0000-22-613-H01-P

1.75

Complex Pneumonia Case

0204-0000-22-614-H01-P

1.25

Evidence-based Practice and Resources

0204-0000-22-647-H04-P

1.0

Cardiovascular Disease: Primary Prevention Case
ACPE #:
 0204-0000-22-605-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including hypertension, dyslipidemia, chronic kidney disease, diabetes, and obesity.
  • State the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendations for adult immunizations.
  • Determine how to advise a patient on point-of-care testing to measure response to drug therapy.
  • Discuss national benchmarking standards and implications to patient care.

Cardiovascular Disease: Secondary Prevention Case
ACPE#: 0204-0000-22-606-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including atrial fibrillation (AF), acute coronary syndromes (ACS), and gastroesophageal reflux disease (GERD).
  • Develop a plan to address continuity of care issues.
  • Formulate a medication therapy plan for smoking cessation.
  • Determine how to manage drug – drug and drug-induced disease interactions in a patient with ischemic heart disease.
  • Discuss quality of life in this population.
  • Discuss national benchmarking standards and implications to patient care.

Complex Heart Failure Case
ACPE #:
 0204-0000-22-607-H01-P

  • Select optimal treatment and monitoring for a complex patient-case with multiple conditions, including heart failure, electrolyte disturbances in acute decompensated heart failure, diabetes, and a thyroid disorder.
  • Discuss the medications that should be avoided in heart failure.
  • Identify safety issues in this population.
  • Define inadequate health literacy in this population.

Providing Safe and Effective Pharmacotherapy: Key Regulatory and Quality Approaches
ACPE #: 
0204-0000-22-608-H05-P

  • Explain the regulatory and accreditation requirements of a comprehensive medication use program.
  • Describe methods to develop and maintain a medication use system.
  • Discuss technology used to promote safe and effective medication use.
  • Apply national regulations and evidence-based practices for medication safety and quality.
  • Interpret results from pharmacotherapy-related quality improvement activities.

Research Methods and Data Analysis
ACPE #:
 0204-0000-22-609-H04-P

  • Analyze biomedical literature with regard to study methodology, statistical analysis, and significance.
  • Explain the use of evidence-based treatment guidelines and protocols.
  • Interpret the biomedical literature and its application to clinical practice.

Oncology and Supportive Care Case
ACPE #:
 0204-0000-22-610-H01-P

  • Select the appropriate treatment and monitoring of a complex patient-case with multiple conditions, including breast cancer, febrile neutropenia, and pulmonary embolism.
  • compare and contrast current breast cancer screening recommendations.
  • Develop a plan to manage pain and nausea/vomiting in a patient with cancer.
  • Discuss safety issues in this population.
  • Discuss adherence issues with oral chemotherapy regimens.

Complex Nursing Home Patient Case
ACPE #:
 0204-0000-22-611-H01-P

  • Select the appropriate treatment for a complex patient-case with multiple conditions, including stroke, depression/anxiety, dementia, chronic obstructive pulmonary disease (COPD) management, osteoarthritis, osteoporosis, and pain.
  • Discuss complementary/alternative medicine and safety issues in this population.
  • Discuss quality improvement initiatives and regulations in the nursing home setting. 

Complex HIV/AIDS Case
ACPE #:
 0204-0000-22-612-H02-P

  • Select the appropriate treatment and monitoring of a complex patient-case with multiple conditions, including dyslipidemia, and hepatitis B.
  • Identify and manage common drug interactions experienced by HIV-treated patients.
  • Identify and manage common adverse drug reactions experienced by HIV-treated patients.
  • Determine appropriate medication choices for the treatment and prevention of common opportunistic infections.
  • Discuss quality of life issues in terms of medication therapy for HIV-infected patients.
  • Identify and recommend appropriate resource organizations/groups to assist a specific patient. 

Complex Pediatric Asthma Case
ACPE #: 
0204-0000-22-613-H01-P

  • Select optimal treatment and monitoring for a complex patient-case with acute asthma exacerbation, acute otitis media, and seasonal allergies.
  • Apply methods for counseling a patient and/or caregiver in asthma self-management with comprehensive documentation of the patient counseling.
  • Develop a plan for childhood vaccinations in a child who has been delayed in receiving them.
  • Implement principles of shared-decision making and culturally effective care when using complementary/alternative medicine in a pediatric patient. 

Complex Pneumonia Case
ACPE #: 0204-0000-22-614-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including pneumonia, acute renal insufficiency, sepsis, chronic obstructive pulmonary disease (COPD), and dehydration.
  • Interpret clinical data, including lab, physical examination and vital signs.
  • Determine and prioritize pneumonia-related treatment goals.
  • Determine approaches to manage drug allergies and select next best drug therapy when primary drugs are precluded.
  • Discuss approaches to limiting antimicrobial over use by stewarding antibiotic usage appropriately.
  • Discuss safety issues in patients receiving treatment for pneumonia.

Evidence-based Practice and Resources
ACPE#: 0204-0000-22-647-H01-P

  • Identify sources of information to use to answer questions in one’s practice, or from patients and healthcare professionals.
  • Explain how to provide education regarding evidence-based practice to current and future health care professionals.

Core Therapeutic Modules

The Core Therapeutic Modules Review Package consists of 16 activities in which faculty review clinical topics and practice skills using a case-based approach. The activities are designed to assist the learner in identifying knowledge gaps in preparation for a pharmacy specialty board examination. In addition to a recorded presentation, each activity includes links to resources for further self-study and a practice test developed in the same format and rigor as the specialty exam.

Learning Activity

ACPE Number

Contact Hours

ACPE Expiration Date

Select Topics in Infectious Diseases: Part 1

0204-0000-22-615-H01-P

1.0

11/23/25

Select Topics in Infectious Diseases: Part 2

0204-0000-22-616-H01-P

1.0

11/23/25

Statistics, Evidence-Based Medicine, and Clinical Trial Design

0204-0000-21-985-H04-P

2.0

05/17/24 

Cardiac Arrhythmias and Advanced Cardiac Life Support

0204-0000-20-992-H01-P

1.0

09/23/23 

Pharmacotherapy Considerations in the Management of Shock

0204-0000-21-993-H01-P

1.0

09/23/23 

Fluid, Electrolytes, and Nutrition 

0204-0000-22-617-H01-P

1.0

09/21/25

Select Topics in Men's Health

0204-0000-20-615-H01-P

1.0

11/25/23

Select Topics in Women's Health

0204-0000-20-616-H01-P

1.0

11/25/23

Select Topics in Neurologic Disorders

0204-0000-22-618-H01-P

1.0

11/23/25

Select Topics in Psychiatric Disorders

0204-0000-21-625-H01-P

1.0

11/24/24 

Select Topics in Gastrointestinal Diseases

0204-0000-20-617-H01-P

1.0

11/25/23

Select Topics in Rheumatology

0204-0000-21-626-H01-P

1.0

11/24/24 

Diabetes

0204-0000-22-619-H01-P 1.0 11/23/25

Heart Failure

0204-0000-21-627-H01-P 1.0 11/24/24 

Selected Topics in Renal Disease

0204-0000-21-628-H01-P 1.0 11/24/24 

Patient Education and Health Literacy

0204-0000-21-629-H04-P 1.0 11/24/24 

Core Therapeutic Learning Objectives

After participating in these CPE activities, learners should be able to:

Select Topics in Infectious Diseases: Part 1
ACPE#: 0204-0000-22-615-H01-P

For the following infectious diseases: c.difficile infection, skin and soft tissue infections, upper respiratory tract infections, community acquired pneumonia

  • Interpret laboratory and diagnostic tests.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems.

Select Topics in Infectious Diseases: Part 2
ACPE#: 0204-0000-22-616-H01-P

For the following infectious diseases: sexually transmitted diseases, urinary tract infections, endocarditis, meningitis

  • Interpret laboratory and diagnostic tests.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems.

Statistics, Evidence-Based Medicine, and Clinical Trial Design
ACPE #:
0204-0000-21-985-H04-P

  • Determine quality of a study by examining study design, statistical analysis, quality of conclusions, and interpretation of graphs.
  • Determine clinical and statistical significance.
  • Determine if appropriate statistical tests have been used.
  • Determine whether the study applies to a specified patient population.

Cardiac Arrhythmias and Advanced Cardiac Life Support
ACPE #: 0204-0000-20-992-H01-P

  • Interpret signs, symptoms and diagnostic tests for cardiac arrhythmias.
  • Identify drug-related problems, including drug interactions and adverse effects, associated with pharmacotherapy of cardiac arrhythmias.
  • Identify strategies to prevent drug-induced cardiac arrhythmias.
  • Recommend therapy and monitoring for cardiac arrhythmias based on patient-specific information, current guidelines and Advanced Cardiac Life Support (ACLS) guided therapies. 

Pharmacotherapy Considerations in the Management of Shock
ACPE #: 0204-0000-20-993-H01-P

  • Interpret diagnostic and/or laboratory tests, vital signs, and clinical presentation in order to differentiate types of shock (hypovolemic, distributive, cardiogenic).
  • Compare and contrast the pharmacologic agents utilized in shock.
  • Recommend the most appropriate therapy and monitoring based on patient-specific information and current guidelines for the treatment of shock. 

Fluid, Electrolytes, and Nutrition
ACPE#: 0204-0000-22-617-H01-P

  • Interpret laboratory and diagnostic tests for fluid, electrolyte, and nutrition status.
  • Recommend the most appropriate therapy and monitoring in patients with fluid, electrolyte, and nutritional disorders based on patient-specific information and current guidelines.
  • Apply strategies to manage drug-related electrolyte interactions and nutrient interactions.

Select Topics in Men's Health
ACPE #: 0204-0000-20-615-H01-P

  • Recommend appropriate treatment, monitoring and follow-up plans based on patient-specific information and current guidelines for patients with benign prostatic hyperplasia, erectile dysfunction and testosterone deficiency.
  • Explain screening and treatment of osteoporosis in men.
  • Evaluate the role of prostate cancer screening.
  • Select appropriate treatment for patients with prostate cancer. 

Select Topics in Women's Health
ACPE #: 0204-0000-20-616-H01-P

  • Describe pertinent sex-based differences in pharmacodynamics and pharmacokinetics that affect exposure and response to medications.
  • Select health screenings based on patient-specific information for osteoporosis, breast cancer, endometrial cancer, and cervical cancer.
  • Recommend appropriate treatment, monitoring and follow-up plans based on patient-specific information and current guidelines for osteoporosis and menopausal symptoms.
  • Select appropriate contraceptive options, including emergency contraception, based on patient-specific information.
  • Evaluate safety and efficacy of common therapies used during pregnancy and lactation. 

Select Topics in Neurologic Disorders
ACPE#: 0204-0000-22-618-H01-P

For patients with seizure disorders, Parkinson’s disease, headache and sleep disorders:

  • Evaluate the risks and benefits of drug therapy considering other medication and patient specific factors.
  • Formulate the most appropriate treatment, monitoring and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems.

Select Topics in Psychiatric Disorders
ACPE #: 0204-0000-21-625-H01-P

For patients with bipolar, schizophrenia, anxiety disorders, post-traumatic stress disorder, and/or substance abuse disorder:

  • Interpret basic diagnostic factors, clinical presentation, and target symptoms of selected psychiatric disorders.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems and response to therapy. 

Select Topics in Gastrointestinal Diseases
ACPE #: 0204-0000-20-617-H01-P

For patients with nausea, vomiting, inflammatory bowel disease, gastroesophageal reflux disease, or peptic ulcer disease:

  • Recommend appropriate treatment and monitoring, based on drug-specific variables, patient-specific information and clinical practice guidelines.
  • Evaluate drug-related problems and response to therapy.
  • Recommend modifications of patient-specific treatment plans based on follow up assessment. 

Select Topics in Rheumatology
ACPE #: 0204-0000-21-626-H01-P

For patients with rheumatoid arthritis, osteoarthritis and gout:

  • Formulate the most appropriate treatment and monitoring, based on drug-specific variables, patient-specific information and clinical practice guidelines.
  • Evaluate drug-related problems and response to therapy.
  • Recommend appropriate modifications of patient-specific treatment plans based on follow up assessment. 

Diabetes
ACPE#: 0204-0000-22-619-H01-P

  • Interpret diagnostic and/or laboratory tests in patients with diabetes.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems.

Heart Failure
ACPE #: 0204-0000-21-627-H01-P

  • Interpret diagnostic and/or laboratory tests, vital signs and clinical presentation in patients with heart failure.
  • Formulate the most appropriate treatment and monitoring plans, based patient-specific information and current guidelines for patients with heart failure.
  • Recommend appropriate modifications of patient-specific treatment plans based on follow up assessment in patients with heart failure.

Selected Topics in Renal Disease
ACPE #: 0204-0000-21-628-H01-P

  • For patients with acute kidney injury and chronic kidney disease determine the most appropriate treatment and monitoring based on drug characteristics, patient-specific factors, and current clinical practice guidelines.
  • Manage drug dosing and drug-related complications in patients receiving renal replacement therapy.
  • Identify appropriate modifications to the treatment plans based on follow-up assessment to optimize outcomes. 

Patient Education and Health Literacy
ACPE #: 0204-0000-21-629-H04-P

  • Assess considerations for communicating pharmacotherapy plans to various patient populations, including pediatric patients and geriatric patients, using universal health literacy precautions.
  • Evaluate methods for educating patients and caregivers on safe and appropriate use of medications and devices.

Faculty Bios

Christopher Betz, PharmD, BCPS, FKSHP, FASHP*
Associate Professor, Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Louisville, Kentucky 

Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC*
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts 

Kalin Clifford, PharmD, BCPS, BCGP, FASCP
Associate Professor of Pharmacy Practice, Division of Geriatrics and Pediatrics
Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy
Advanced Practice Pharmacist/Clinical Pharmacy Specialist, Geriatrics & Extended Care
VA North Texas Health Care System
Dallas, Texas 

Lourdes Cross, PharmD, BCACP, CDCEs
Assistant Professor
Sullivan University College of Pharmacy & Health Sciences
Clinical Pharmacy Specialist
University of Louisville Hospital
Louisville, Kentucky
 

Stuart T. Haines, PharmD, BCPS, BCACP, FASHP
Professor and Director, Professional Development
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Patricia C. Kienle, BSPharm, MPA, BCSCP, FASHP
Director, Accreditation and Medication Safety
Cardinal Health Innovative Delivery Systems
Wilkes-Barre, Pennsylvania 

Krutika Mediwala Hornback, PharmD, BCPS, BCIDP
Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacy Specialist
Medical University of South Carolina (MUSC) Health
Infectious Diseases Pharmacy Residency Program Director
MUSC Health
Charleston, South Carolina 

Jill Morgan, PharmD, BCPS, BCPPS
Professor and Chair
University of Maryland School of Pharmacy
Baltimore, Maryland 

Victoria R. Nachar, PharmD, BCOP
Clinical Pharmacist Specialist - Ambulatory Hematology
University of Michigan Rogel Cancer Center
Adjunct Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan 

Marc H. Scheetz, PharmD, MSc, BCPS-AQID, FCCP
Professor of Pharmacy and Pharmacology
Director of Pharmacometrics Center of Excellence
Midwestern University
Downers Grove, Illinois
Infectious Diseases Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois 

Douglas Slain, PharmD, BCPS (AQ-ID), FCCP, FASHP*
Associate Professor and Infectious Diseases Clinical Specialist
West Virginia University School of Pharmacy
Morgantown, West Virginia 

Diana Solomon, PharmD, BCCCP
Critical Care Clinical Pharmacy Specialist
Cooper University HealthCare
Camden, New Jersey 

Trent G. Towne, PharmD, BCPS
Associate Professor of Pharmacy Practice
Manchester University College of Pharmacy
Clinical Pharmacy Specialist, Infectious Disease
Parkview Health System
Fort Wayne, Indiana
 

Kristin Watson, PharmD, BCCP
Associate Professor
University of Maryland School of Pharmacy
Baltimore, Maryland 

Jon Wietholter, PharmD, BCPS, FCCP
Clinical Associate Professor
West Virginia University School of Pharmacy
Internal Medicine Clinical Specialist
WVU Medicine Ruby Memorial Hospital
Morgantown, West Virginia

*Content Matter Experts

Anna M. Jackson, PharmD, BCPS
Tony Martin, PharmD, MBA

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

  • Snehal Bhatt: advisory board, Astra Zeneca; advisory board and speaker’s bureau, Janssen Pharmaceuticals, Inc.
  • Marc Scheetz: NIH, research support; legal consulting, Taylor, English, Duma, LLP, Hall, Booth, Smith, Reminger Co. LPA; consulting/honoraria, uidepoint Global, Spero, Third Pole Therapeutics, Merck, Takeda 

All other persons in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.